Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Mouse dendritic cell migration in abdominal lymph nodes by intraperitoneal administration.

Wang B, Sun C, Wang S, Shang N, Shangguan J, Figini M, Pan L, Zhou K, Ma Q, Procissi D, Velichko Y, Yaghmai V, Li G, Zhang Z.

Am J Transl Res. 2018 Sep 15;10(9):2859-2867. eCollection 2018.

2.

Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.

Figini M, Riva M, Graham M, Castelli GM, Fernandes B, Grimaldi M, Baselli G, Pessina F, Bello L, Zhang H, Bizzi A.

Radiology. 2018 Oct 2:180054. doi: 10.1148/radiol.2018180054. [Epub ahead of print]

PMID:
30277427
3.

Diffusion MRI biomarkers predict the outcome of irreversible electroporation in a pancreatic tumor mouse model.

Figini M, Wang X, Lyu T, Su Z, Wang B, Sun C, Shangguan J, Pan L, Zhou K, Ma Q, Yaghmai V, Procissi D, Larson AC, Zhang Z.

Am J Cancer Res. 2018 Aug 1;8(8):1615-1623. eCollection 2018.

4.

Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Cheung A, Opzoomer J, Ilieva KM, Gazinska P, Hoffmann RM, Mirza H, Marlow R, Francesch-Domenech E, Fittall M, Dominguez Rodriguez D, Clifford A, Badder L, Patel N, Mele S, Pellizzari G, Bax HJ, Crescioli S, Petranyi G, Larcombe-Young D, Josephs DH, Canevari S, Figini M, Pinder S, Nestle FO, Gillett C, Spicer JF, Grigoriadis A, Tutt ANJ, Karagiannis SN.

Clin Cancer Res. 2018 Oct 15;24(20):5098-5111. doi: 10.1158/1078-0432.CCR-18-0652. Epub 2018 Aug 1.

5.

Quantitative measurement of breast carcinoma fibrosis for the prediction in the risk of bone metastasis.

Sun C, Wang B, Li J, Shangguan J, Figini M, Zhou K, Pan L, Ma Q, Zhang Z.

Am J Transl Res. 2018 Jun 15;10(6):1852-1859. eCollection 2018.

6.

Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells.

Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann RE, Iacovelli F, Desideri A, Anichini A, Canevari S, Gianni AM, Figini M.

MAbs. 2018 Oct;10(7):1084-1097. doi: 10.1080/19420862.2018.1494105. Epub 2018 Aug 6.

PMID:
29993310
7.

Combined magnetic resonance imaging and optical surgical navigation system guidance of percutaneous liver cryoablation in a porcine model.

Zhou K, Zhang Z, Figini M, Shangguan J, Wang Y, Shi H, Li Y, Jin Z, Pan J.

Am J Transl Res. 2018 May 15;10(5):1531-1538. eCollection 2018.

8.

An immunologically relevant rodent model demonstrates safety of therapy using a tumour-specific IgE.

Josephs DH, Nakamura M, Bax HJ, Dodev TS, Muirhead G, Saul L, Karagiannis P, Ilieva KM, Crescioli S, Gazinska P, Woodman N, Lombardelli C, Kareemaghay S, Selkirk C, Lentfer H, Barton C, Canevari S, Figini M, Downes N, Dombrowicz D, Corrigan CJ, Nestle FO, Jones PS, Gould HJ, Blower PJ, Tsoka S, Spicer JF, Karagiannis SN.

Allergy. 2018 Apr 13. doi: 10.1111/all.13455. [Epub ahead of print]

PMID:
29654623
9.

Evaluation of Antigen-Conjugated Fluorescent Beads to Identify Antigen-Specific B Cells.

Correa I, Ilieva KM, Crescioli S, Lombardi S, Figini M, Cheung A, Spicer JF, Tutt ANJ, Nestle FO, Karagiannis P, Lacy KE, Karagiannis SN.

Front Immunol. 2018 Mar 23;9:493. doi: 10.3389/fimmu.2018.00493. eCollection 2018.

10.

An image registration protocol to integrate electrophysiology, MRI and neuropathology data in epileptic patients explored with intracerebral electrodes.

Zucca I, Milesi G, Padelli F, Rossini L, Gozzo F, Figini M, Barbaglia A, Cardinale F, Tassi L, Bruzzone MG, Spreafico R, Garbelli R.

J Neurosci Methods. 2018 Jun 1;303:159-168. doi: 10.1016/j.jneumeth.2018.03.016. Epub 2018 Mar 27.

PMID:
29601885
11.

MRI-guided interventional natural killer cell delivery for liver tumor treatment.

Su Z, Wang X, Zheng L, Lyu T, Figini M, Wang B, Procissi D, Shangguan J, Sun C, Pan L, Qin L, Zhang B, Velichko Y, Salem R, Yaghmai V, Larson AC, Zhang Z.

Cancer Med. 2018 May;7(5):1860-1869. doi: 10.1002/cam4.1459. Epub 2018 Mar 30.

12.

Therapeutic management of classic lichen planopilaris: a systematic review.

Errichetti E, Figini M, Croatto M, Stinco G.

Clin Cosmet Investig Dermatol. 2018 Feb 27;11:91-102. doi: 10.2147/CCID.S137870. eCollection 2018. Review.

13.

Multi-parameter evaluation of lumbar intervertebral disc degeneration using quantitative magnetic resonance imaging techniques.

Xiong X, Zhou Z, Figini M, Shangguan J, Zhang Z, Chen W.

Am J Transl Res. 2018 Feb 15;10(2):444-454. eCollection 2018.

14.

Selective targeting and degradation of doxorubicin-loaded folate-functionalized DNA nanocages.

Raniolo S, Vindigni G, Ottaviani A, Unida V, Iacovelli F, Manetto A, Figini M, Stella L, Desideri A, Biocca S.

Nanomedicine. 2018 Feb 17;14(4):1181-1190. doi: 10.1016/j.nano.2018.02.002. [Epub ahead of print]

PMID:
29458213
15.

18F-FDG PET Biomarkers Help Detect Early Metabolic Response to Irreversible Electroporation and Predict Therapeutic Outcomes in a Rat Liver Tumor Model.

Wang X, Su Z, Lyu T, Figini M, Procissi D, Shangguan J, Sun C, Wang B, Shang N, Gu S, Ma Q, Gordon AC, Lin K, Wang J, Lewandowski RJ, Salem R, Yaghmai V, Larson AC, Zhang Z.

Radiology. 2018 Apr;287(1):137-145. doi: 10.1148/radiol.2017170920. Epub 2017 Dec 12.

PMID:
29232185
16.

Dendritic cells based immunotherapy.

Shang N, Figini M, Shangguan J, Wang B, Sun C, Pan L, Ma Q, Zhang Z.

Am J Cancer Res. 2017 Oct 1;7(10):2091-2102. eCollection 2017. Review.

17.

Image-guided dendritic cell-based vaccine immunotherapy in murine carcinoma models.

Wang B, Sun C, Wang S, Shang N, Figini M, Ma Q, Gu S, Procissi D, Yaghmai V, Li G, Larson A, Zhang Z.

Am J Transl Res. 2017 Oct 15;9(10):4564-4573. eCollection 2017. Review.

18.

Tumor angiogenesis and bone metastasis - Correlation in invasive breast carcinoma.

Sun C, Li J, Wang B, Shangguan J, Figini M, Shang N, Pan L, Zhang Z.

J Immunol Methods. 2018 Jan;452:46-52. doi: 10.1016/j.jim.2017.10.006. Epub 2017 Oct 21.

PMID:
29066178
19.

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields.

Ilieva KM, Fazekas-Singer J, Achkova DY, Dodev TS, Mele S, Crescioli S, Bax HJ, Cheung A, Karagiannis P, Correa I, Figini M, Marlow R, Josephs DH, Beavil AJ, Maher J, Spicer JF, Jensen-Jarolim E, Tutt AN, Karagiannis SN.

Front Immunol. 2017 Sep 11;8:1112. doi: 10.3389/fimmu.2017.01112. eCollection 2017.

20.

Irreversible electroporation in primary and metastatic hepatic malignancies: A review.

Lyu T, Wang X, Su Z, Shangguan J, Sun C, Figini M, Wang J, Yaghmai V, Larson AC, Zhang Z.

Medicine (Baltimore). 2017 Apr;96(17):e6386. doi: 10.1097/MD.0000000000006386. Review.

21.

A longitudinal DTI and histological study of the spinal cord reveals early pathological alterations in G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

Marcuzzo S, Bonanno S, Figini M, Scotti A, Zucca I, Minati L, Riva N, Domi T, Fossaghi A, Quattrini A, Galbardi B, D'Alessandro S, Bruzzone MG, García-Verdugo JM, Moreno-Manzano V, Mantegazza R, Bernasconi P.

Exp Neurol. 2017 Jul;293:43-52. doi: 10.1016/j.expneurol.2017.03.018. Epub 2017 Mar 27.

PMID:
28351750
22.

Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging.

Figini M, Wang X, Lyu T, Su Z, Procissi D, Yaghmai V, Larson AC, Zhang Z.

Am J Transl Res. 2017 Feb 15;9(2):580-590. eCollection 2017.

23.

Anti-Folate Receptor-α IgE but not IgG Recruits Macrophages to Attack Tumors via TNFα/MCP-1 Signaling.

Josephs DH, Bax HJ, Dodev T, Georgouli M, Nakamura M, Pellizzari G, Saul L, Karagiannis P, Cheung A, Herraiz C, Ilieva KM, Correa I, Fittall M, Crescioli S, Gazinska P, Woodman N, Mele S, Chiaruttini G, Gilbert AE, Koers A, Bracher M, Selkirk C, Lentfer H, Barton C, Lever E, Muirhead G, Tsoka S, Canevari S, Figini M, Montes A, Downes N, Dombrowicz D, Corrigan CJ, Beavil AJ, Nestle FO, Jones PS, Gould HJ, Sanz-Moreno V, Blower PJ, Spicer JF, Karagiannis SN.

Cancer Res. 2017 Mar 1;77(5):1127-1141. doi: 10.1158/0008-5472.CAN-16-1829. Epub 2017 Jan 17.

24.

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, Valdagni R, Mezzanzanica D, Boerman O, Canevari S, Figini M.

Oncotarget. 2017 Feb 14;8(7):10919-10930. doi: 10.18632/oncotarget.14229.

25.

Comparison of Diffusion MRI Acquisition Protocols for the In Vivo Characterization of the Mouse Spinal Cord: Variability Analysis and Application to an Amyotrophic Lateral Sclerosis Model.

Figini M, Scotti A, Marcuzzo S, Bonanno S, Padelli F, Moreno-Manzano V, García-Verdugo JM, Bernasconi P, Mantegazza R, Bruzzone MG, Zucca I.

PLoS One. 2016 Aug 25;11(8):e0161646. doi: 10.1371/journal.pone.0161646. eCollection 2016.

26.

Effective adoptive immunotherapy of triple-negative breast cancer by folate receptor-alpha redirected CAR T cells is influenced by surface antigen expression level.

Song DG, Ye Q, Poussin M, Chacon JA, Figini M, Powell DJ Jr.

J Hematol Oncol. 2016 Jul 20;9(1):56. doi: 10.1186/s13045-016-0285-y.

27.

Targeting folate receptor alpha for cancer treatment.

Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN.

Oncotarget. 2016 Aug 9;7(32):52553-52574. doi: 10.18632/oncotarget.9651. Review.

28.

In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.

Mazzocco C, Fracasso G, Germain-Genevois C, Dugot-Senant N, Figini M, Colombatti M, Grenier N, Couillaud F.

Sci Rep. 2016 Mar 21;6:23314. doi: 10.1038/srep23314.

29.

Type II focal cortical dysplasia: Ex vivo 7T magnetic resonance imaging abnormalities and histopathological comparisons.

Zucca I, Milesi G, Medici V, Tassi L, Didato G, Cardinale F, Tringali G, Colombo N, Bramerio M, D'Incerti L, Freri E, Morbin M, Fugnanesi V, Figini M, Spreafico R, Garbelli R.

Ann Neurol. 2016 Jan;79(1):42-58. doi: 10.1002/ana.24541. Epub 2015 Nov 26.

PMID:
26448158
30.

Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen.

Frigerio B, Benigni F, Luison E, Seregni E, Pascali C, Fracasso G, Morlino S, Valdagni R, Mezzanzanica D, Canevari S, Figini M.

Immunol Lett. 2015 Nov;168(1):105-10. doi: 10.1016/j.imlet.2015.09.012. Epub 2015 Sep 25.

PMID:
26404855
31.

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.

Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ Jr.

Oncotarget. 2015 Oct 6;6(30):28911-28. doi: 10.18632/oncotarget.5029.

32.

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity.

Song DG, Ye Q, Poussin M, Liu L, Figini M, Powell DJ Jr.

Oncotarget. 2015 Aug 28;6(25):21533-46.

33.

Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions.

Doro F, Colombo C, Alberti C, Arosio D, Belvisi L, Casagrande C, Fanelli R, Manzoni L, Parisini E, Piarulli U, Luison E, Figini M, Tomassetti A, Civera M.

Org Biomol Chem. 2015 Mar 7;13(9):2570-3. doi: 10.1039/c4ob02538e.

34.

Mathematical models for the diffusion magnetic resonance signal abnormality in patients with prion diseases.

Figini M, Alexander DC, Redaelli V, Fasano F, Grisoli M, Baselli G, Gambetti P, Tagliavini F, Bizzi A.

Neuroimage Clin. 2014 Nov 29;7:142-54. doi: 10.1016/j.nicl.2014.11.017. eCollection 2015.

35.

Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo.

Quarta A, Bernareggi D, Benigni F, Luison E, Nano G, Nitti S, Cesta MC, Di Ciccio L, Canevari S, Pellegrino T, Figini M.

Nanoscale. 2015 Feb 14;7(6):2336-51. doi: 10.1039/c4nr04426f.

PMID:
25504081
36.

In vivo DTI tractography of the rat brain: an atlas of the main tracts in Paxinos space with histological comparison.

Figini M, Zucca I, Aquino D, Pennacchio P, Nava S, Di Marzio A, Preti MG, Baselli G, Spreafico R, Frassoni C.

Magn Reson Imaging. 2015 Apr;33(3):296-303. doi: 10.1016/j.mri.2014.11.001. Epub 2014 Dec 5.

PMID:
25482578
37.

7T MRI features in control human hippocampus and hippocampal sclerosis: an ex vivo study with histologic correlations.

Coras R, Milesi G, Zucca I, Mastropietro A, Scotti A, Figini M, Mühlebner A, Hess A, Graf W, Tringali G, Blümcke I, Villani F, Didato G, Frassoni C, Spreafico R, Garbelli R.

Epilepsia. 2014 Dec;55(12):2003-16. doi: 10.1111/epi.12828. Epub 2014 Nov 3.

38.

Potential use of human adipose mesenchymal stromal cells for intervertebral disc regeneration: a preliminary study on biglycan-deficient murine model of chronic disc degeneration.

Marfia G, Campanella R, Navone SE, Zucca I, Scotti A, Figini M, Di Vito C, Alessandri G, Riboni L, Parati E.

Arthritis Res Ther. 2014 Oct 8;16(5):457. doi: 10.1186/s13075-014-0457-5.

39.

PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models.

Zuccolotto G, Fracasso G, Merlo A, Montagner IM, Rondina M, Bobisse S, Figini M, Cingarlini S, Colombatti M, Zanovello P, Rosato A.

PLoS One. 2014 Oct 3;9(10):e109427. doi: 10.1371/journal.pone.0109427. eCollection 2014.

40.

The CONNECT project: Combining macro- and micro-structure.

Assaf Y, Alexander DC, Jones DK, Bizzi A, Behrens TE, Clark CA, Cohen Y, Dyrby TB, Huppi PS, Knoesche TR, Lebihan D, Parker GJ, Poupon C; CONNECT consortium, Anaby D, Anwander A, Bar L, Barazany D, Blumenfeld-Katzir T, De-Santis S, Duclap D, Figini M, Fischi E, Guevara P, Hubbard P, Hofstetter S, Jbabdi S, Kunz N, Lazeyras F, Lebois A, Liptrot MG, Lundell H, Mangin JF, Dominguez DM, Morozov D, Schreiber J, Seunarine K, Nava S, Poupon C, Riffert T, Sasson E, Schmitt B, Shemesh N, Sotiropoulos SN, Tavor I, Zhang HG, Zhou FL.

Neuroimage. 2013 Oct 15;80:273-82. doi: 10.1016/j.neuroimage.2013.05.055. Epub 2013 May 28.

41.

Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.

Satta A, Mezzanzanica D, Turatti F, Canevari S, Figini M.

Future Oncol. 2013 Apr;9(4):527-39. doi: 10.2217/fon.12.203. Review.

PMID:
23560375
42.

A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.

Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S, Figini M.

Eur J Cancer. 2013 Jun;49(9):2223-32. doi: 10.1016/j.ejca.2013.01.024. Epub 2013 Feb 20.

PMID:
23433847
43.

Redundant and antagonistic functions of galectin-1, -3, and -8 in the elicitation of T cell responses.

Tribulatti MV, Figini MG, Carabelli J, Cattaneo V, Campetella O.

J Immunol. 2012 Apr 1;188(7):2991-9. doi: 10.4049/jimmunol.1102182. Epub 2012 Feb 22.

44.

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ Jr.

Blood. 2012 Jan 19;119(3):696-706. doi: 10.1182/blood-2011-03-344275. Epub 2011 Nov 23.

45.

Antitumor effects of a human dimeric antibody fragment 131I-AFRA-DFM5.3 in a mouse model for ovarian cancer.

Zacchetti A, Martin F, Luison E, Coliva A, Bombardieri E, Allegretti M, Figini M, Canevari S.

J Nucl Med. 2011 Dec;52(12):1938-46. doi: 10.2967/jnumed.110.086819. Epub 2011 Nov 8.

46.

Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.

Burastero SE, Frigerio B, Lopalco L, Sironi F, Breda D, Longhi R, Scarlatti G, Canevari S, Figini M, Lusso P.

PLoS One. 2011;6(7):e22081. doi: 10.1371/journal.pone.0022081. Epub 2011 Jul 19.

47.

Harnessing engineered antibodies of the IgE class to combat malignancy: initial assessment of FcɛRI-mediated basophil activation by a tumour-specific IgE antibody to evaluate the risk of type I hypersensitivity.

Rudman SM, Josephs DH, Cambrook H, Karagiannis P, Gilbert AE, Dodev T, Hunt J, Koers A, Montes A, Taams L, Canevari S, Figini M, Blower PJ, Beavil AJ, Nicodemus CF, Corrigan C, Kaye SB, Nestle FO, Gould HJ, Spicer JF, Karagiannis SN.

Clin Exp Allergy. 2011 Oct;41(10):1400-13. doi: 10.1111/j.1365-2222.2011.03770.x. Epub 2011 May 16.

PMID:
21569129
48.

In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr.

Cancer Res. 2011 Jul 1;71(13):4617-27. doi: 10.1158/0008-5472.CAN-11-0422. Epub 2011 May 5.

49.

Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.

Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.

J Cell Physiol. 2010 Oct;225(1):256-65. doi: 10.1002/jcp.22257.

PMID:
20506359
50.

Pharmacokinetics of orally administered melatonin in critically ill patients.

Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, Ruscica M, Dozio E, Esposti R, DeMartini G, Fraschini F, Rezzani R, Reiter RJ, Iapichino G.

J Pineal Res. 2010 Mar;48(2):142-7. doi: 10.1111/j.1600-079X.2009.00737.x. Epub 2010 Jan 8.

PMID:
20070489

Supplemental Content

Loading ...
Support Center